Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*
Derek C. Angus(University of Pittsburgh), Ben van Hout(The Open Group), Daniel Ball(Eli Lilly (United States)), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Bruce R. Basson(Universitat Autònoma de Barcelona), Gordon R. Bernard(Vanderbilt University Medical Center), Walter T. Linde‐Zwirble(Tokyo Health Care University), E. Wesley Ely(Vanderbilt University), Gilles Clermont(Tokyo Health Care University), Jean‐Louis Vincent(Université Libre de Bruxelles)
Cited by 226
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure
|Intensive Care Medicine|1996|11.7k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k